Brief: Inhibikase Therapeutics Announces Pricing Of Registered Direct Offering And Warrant Inducement, Priced At-The-Market For Aggregate Gross Proceeds Of $4.0 Million
20/05/2024 14:01
May 20 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF REGISTERED
DIRECT
OFFERING AND WARRANT INDUCEMENT, PRICED AT-THE-MARKET FOR
AGGREGATE GROSS PROCEEDS OF $4.0 MILLION
* INHIBIKASE SETS WARRANTS EXERCISE PRICE AT $1.68
* INHIBIKASE THERAPEUTICS- ENTERED A SECURITIES PURCHASE
AGREEMENT
WITH A SINGLE INSTITUTIONAL INVESTOR TO PURCHASE 1.7 MILLION
SHARES OF COMMON STOCK
Source text for Eikon: ID:nGNXcc2WWC
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary